Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Stock Information for Tonix Pharmaceuticals Holding Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tonix Pharmaceuticals Holding Corp.

Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA(TM) and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
Tonix Pharmaceuticals to Present Poster on Tonmya(TM) at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA(TM) (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.